Interferon-β is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis

Background: Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Objectives: Our objective was to characterize the role of IFN-β in immune regulation in experimental autoimmune encephalomyelitis (EAE). Methods: IFN-β...

Full description

Saved in:
Bibliographic Details
Published inMultiple sclerosis Vol. 16; no. 12; pp. 1458 - 1473
Main Authors Galligan, CL, Pennell, LM, Murooka, TT, Baig, E, Majchrzak-Kita, B, Rahbar, R, Fish, EN
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.12.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Objectives: Our objective was to characterize the role of IFN-β in immune regulation in experimental autoimmune encephalomyelitis (EAE). Methods: IFN-β +/+ and IFN-β—/— mice were immunized with myelin oligodendrocyte glycoprotein peptide in the presence or absence of IFN-β, to induce EAE. Disease pathogenesis was monitored in the context of incidence, time of onset, clinical score, and immune cell activation in the brains, spleens and lymph nodes of affected mice. Results: Compared with IFN-β+/+ mice, IFN-β—/ — mice exhibited an earlier onset and a more rapid progression of EAE, increased numbers of CD11b+ leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the central nervous system and draining lymph nodes. IFN-β treatment delayed disease onset and reduced disease severity. Ex vivo experiments revealed that the lack of IFN-β results in enhanced generation of autoreactive T cells, a likely consequence of the absence of IFN-β-regulated events in both the CD4+ T cells and antigen-presenting dendritic cells. Gene expression analysis of IFN-β-treated bone marrow macrophages (CD11b +) identified modulation of genes affecting T cell proliferation and Th17 differentiation. Conclusions: We conclude that IFN-β acts to suppress the generation of autoimmune-inducing Th17 cells during the development of disease as well as modulating pro-inflammatory mediators.
AbstractList Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Our objective was to characterize the role of IFN-β in immune regulation in experimental autoimmune encephalomyelitis (EAE). IFN-β(+/+) and IFN-β(-/-) mice were immunized with myelin oligodendrocyte glycoprotein peptide in the presence or absence of IFN-β, to induce EAE. Disease pathogenesis was monitored in the context of incidence, time of onset, clinical score, and immune cell activation in the brains, spleens and lymph nodes of affected mice. Compared with IFN-β(+/+) mice, IFN-β(-/-) mice exhibited an earlier onset and a more rapid progression of EAE, increased numbers of CD11b(+) leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the central nervous system and draining lymph nodes. IFN-β treatment delayed disease onset and reduced disease severity. Ex vivo experiments revealed that the lack of IFN-β results in enhanced generation of autoreactive T cells, a likely consequence of the absence of IFN-β-regulated events in both the CD4(+) T cells and antigen-presenting dendritic cells. Gene expression analysis of IFN-β-treated bone marrow macrophages (CD11b(+)) identified modulation of genes affecting T cell proliferation and Th17 differentiation. We conclude that IFN-β acts to suppress the generation of autoimmune-inducing Th17 cells during the development of disease as well as modulating pro-inflammatory mediators.
Background: Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Objectives: Our objective was to characterize the role of IFN-β in immune regulation in experimental autoimmune encephalomyelitis (EAE). Methods: IFN-β +/+ and IFN-β—/— mice were immunized with myelin oligodendrocyte glycoprotein peptide in the presence or absence of IFN-β, to induce EAE. Disease pathogenesis was monitored in the context of incidence, time of onset, clinical score, and immune cell activation in the brains, spleens and lymph nodes of affected mice. Results: Compared with IFN-β+/+ mice, IFN-β—/ — mice exhibited an earlier onset and a more rapid progression of EAE, increased numbers of CD11b+ leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the central nervous system and draining lymph nodes. IFN-β treatment delayed disease onset and reduced disease severity. Ex vivo experiments revealed that the lack of IFN-β results in enhanced generation of autoreactive T cells, a likely consequence of the absence of IFN-β-regulated events in both the CD4+ T cells and antigen-presenting dendritic cells. Gene expression analysis of IFN-β-treated bone marrow macrophages (CD11b +) identified modulation of genes affecting T cell proliferation and Th17 differentiation. Conclusions: We conclude that IFN-β acts to suppress the generation of autoimmune-inducing Th17 cells during the development of disease as well as modulating pro-inflammatory mediators.
Background: Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Objectives: Our objective was to characterize the role of IFN-β in immune regulation in experimental autoimmune encephalomyelitis (EAE). Methods: IFN-β +/+ and IFN-β —/— mice were immunized with myelin oligodendrocyte glycoprotein peptide in the presence or absence of IFN-β, to induce EAE. Disease pathogenesis was monitored in the context of incidence, time of onset, clinical score, and immune cell activation in the brains, spleens and lymph nodes of affected mice. Results: Compared with IFN-β +/+ mice, IFN-β —/ — mice exhibited an earlier onset and a more rapid progression of EAE, increased numbers of CD11b + leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the central nervous system and draining lymph nodes. IFN-β treatment delayed disease onset and reduced disease severity. Ex vivo experiments revealed that the lack of IFN-β results in enhanced generation of autoreactive T cells, a likely consequence of the absence of IFN-β-regulated events in both the CD4 + T cells and antigen-presenting dendritic cells. Gene expression analysis of IFN-β-treated bone marrow macrophages (CD11b + ) identified modulation of genes affecting T cell proliferation and Th17 differentiation. Conclusions: We conclude that IFN-β acts to suppress the generation of autoimmune-inducing Th17 cells during the development of disease as well as modulating pro-inflammatory mediators.
BACKGROUNDInterferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined.OBJECTIVESOur objective was to characterize the role of IFN-β in immune regulation in experimental autoimmune encephalomyelitis (EAE).METHODSIFN-β(+/+) and IFN-β(-/-) mice were immunized with myelin oligodendrocyte glycoprotein peptide in the presence or absence of IFN-β, to induce EAE. Disease pathogenesis was monitored in the context of incidence, time of onset, clinical score, and immune cell activation in the brains, spleens and lymph nodes of affected mice.RESULTSCompared with IFN-β(+/+) mice, IFN-β(-/-) mice exhibited an earlier onset and a more rapid progression of EAE, increased numbers of CD11b(+) leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the central nervous system and draining lymph nodes. IFN-β treatment delayed disease onset and reduced disease severity. Ex vivo experiments revealed that the lack of IFN-β results in enhanced generation of autoreactive T cells, a likely consequence of the absence of IFN-β-regulated events in both the CD4(+) T cells and antigen-presenting dendritic cells. Gene expression analysis of IFN-β-treated bone marrow macrophages (CD11b(+)) identified modulation of genes affecting T cell proliferation and Th17 differentiation.CONCLUSIONSWe conclude that IFN-β acts to suppress the generation of autoimmune-inducing Th17 cells during the development of disease as well as modulating pro-inflammatory mediators.
Background: Interferon (IFN)- beta is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Objectives: Our objective was to characterize the role of IFN- beta in immune regulation in experimental autoimmune encephalomyelitis (EAE). Methods: IFN- beta +/+ and IFN- beta -/- mice were immunized with myelin oligodendrocyte glycoprotein peptide in the presence or absence of IFN- beta , to induce EAE. Disease pathogenesis was monitored in the context of incidence, time of onset, clinical score, and immune cell activation in the brains, spleens and lymph nodes of affected mice. Results: Compared with IFN- beta +/+ mice, IFN- beta -/ - mice exhibited an earlier onset and a more rapid progression of EAE, increased numbers of CD11b+ leukocytes infiltrating affected brains and an increased percentage of Th17 cells in the central nervous system and draining lymph nodes. IFN- beta treatment delayed disease onset and reduced disease severity. Ex vivo experiments revealed that the lack of IFN- beta results in enhanced generation of autoreactive T cells, a likely consequence of the absence of IFN- beta -regulated events in both the CD4+ T cells and antigen-presenting dendritic cells. Gene expression analysis of IFN- beta -treated bone marrow macrophages (CD11b +) identified modulation of genes affecting T cell proliferation and Th17 differentiation. Conclusions: We conclude that IFN- beta acts to suppress the generation of autoimmune-inducing Th17 cells during the development of disease as well as modulating pro-inflammatory mediators.
Author Majchrzak-Kita, B
Pennell, LM
Murooka, TT
Baig, E
Fish, EN
Galligan, CL
Rahbar, R
Author_xml – sequence: 1
  givenname: CL
  surname: Galligan
  fullname: Galligan, CL
  organization: Toronto General Research Institute, University Health Network, Toronto, Canada/Department of Immunology, University of Toronto, Toronto, Canada
– sequence: 2
  givenname: LM
  surname: Pennell
  fullname: Pennell, LM
  organization: Toronto General Research Institute, University Health Network, Toronto, Canada/Department of Immunology, University of Toronto, Toronto, Canada
– sequence: 3
  givenname: TT
  surname: Murooka
  fullname: Murooka, TT
  organization: Toronto General Research Institute, University Health Network, Toronto, Canada/Department of Immunology, University of Toronto, Toronto, Canada
– sequence: 4
  givenname: E
  surname: Baig
  fullname: Baig, E
  organization: Toronto General Research Institute, University Health Network, Toronto, Canada/Department of Immunology, University of Toronto, Toronto, Canada
– sequence: 5
  givenname: B
  surname: Majchrzak-Kita
  fullname: Majchrzak-Kita, B
  organization: Toronto General Research Institute, University Health Network, Toronto, Canada/Department of Immunology, University of Toronto, Toronto, Canada
– sequence: 6
  givenname: R
  surname: Rahbar
  fullname: Rahbar, R
  organization: Toronto General Research Institute, University Health Network, Toronto, Canada/Department of Immunology, University of Toronto, Toronto, Canada
– sequence: 7
  givenname: EN
  surname: Fish
  fullname: Fish, EN
  email: en.fish@utoronto.ca
  organization: Toronto General Research Institute, University Health Network, Toronto, Canada/Department of Immunology, University of Toronto, Toronto, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20935030$$D View this record in MEDLINE/PubMed
BookMark eNqFkTtPwzAQxy1URFtgZ0LemAJ-xHE8oopHpUosMEdOei4piV3sBJGvxQfhM-GqhQEJ4eV8d7_76x5TNLLOAkJnlFxSKuUV5YKlIheU8JwyoQ7QhKZSJkRJMor_mE62-TGahrAmhEjJxREaM6K4IJxM0GpuO_AGvLPJ5weuA9b4BQbsYdU3unMeO4M33tXWNLptt5EBwxvYLuDaYnjfgK_b6OoG675zddv2FjDYCjbPunHtAE3d1eEEHRrdBDjd22P0dHvzOLtPFg9389n1Iql4lneJVLrkpcipkCrXBASHOFCWCsorxijjQuVgjBJlJoQyaU4pTbPMsGWlsiUwfowudrqx59ceQle0daigabQF14cilymVipDsf5KK-FjGI0l2ZOVdCB5MsYkzaz8UlBTbOxS_7xBLzvfifdnC8qfge_ERSHZA0Cso1q73Nq7lb8EvzkGSgg
CitedBy_id crossref_primary_10_3389_fimmu_2022_972127
crossref_primary_10_3390_molecules27061763
crossref_primary_10_1111_j_1476_5381_2011_01461_x
crossref_primary_10_1186_s13041_024_01077_7
crossref_primary_10_3389_fnins_2021_685645
crossref_primary_10_4155_fmc_2017_0322
crossref_primary_10_1189_jlb_3A1214_598R
crossref_primary_10_3389_fimmu_2020_606456
crossref_primary_10_1038_s41598_022_21850_9
crossref_primary_10_2139_ssrn_4020791
crossref_primary_10_1016_j_bcp_2024_116082
crossref_primary_10_1186_1742_2094_8_181
crossref_primary_10_1016_j_it_2011_03_008
crossref_primary_10_1074_jbc_M114_602474
crossref_primary_10_2217_bmm_12_10
crossref_primary_10_4049_jimmunol_1500411
crossref_primary_10_1371_journal_pone_0118830
crossref_primary_10_1089_jir_2013_0088
crossref_primary_10_1155_2012_970789
crossref_primary_10_1016_j_clim_2016_06_015
crossref_primary_10_1111_imm_12781
crossref_primary_10_1007_s13770_017_0101_y
crossref_primary_10_2174_1871530319666190729112246
crossref_primary_10_3390_ijms20010190
crossref_primary_10_1016_j_neuropharm_2016_04_009
crossref_primary_10_1016_j_nbd_2019_02_014
crossref_primary_10_1186_s12974_015_0427_0
crossref_primary_10_1111_jcmm_15928
crossref_primary_10_4161_bioe_22835
crossref_primary_10_1016_j_febslet_2011_05_030
crossref_primary_10_1111_j_1600_065X_2012_01131_x
crossref_primary_10_1002_glia_24494
crossref_primary_10_1177_1352458518805246
crossref_primary_10_2174_1570159X19666210924110144
crossref_primary_10_1016_j_cytogfr_2016_03_013
crossref_primary_10_1016_j_imlet_2014_03_006
crossref_primary_10_1111_imm_13569
crossref_primary_10_4049_jimmunol_1200141
crossref_primary_10_1111_bph_13674
crossref_primary_10_1177_1352458514561909
crossref_primary_10_1002_art_34589
crossref_primary_10_1002_glia_22608
crossref_primary_10_1084_jem_20201796
crossref_primary_10_4049_jimmunol_1501053
Cites_doi 10.1016/S0002-9440(10)63416-5
10.1016/S0171-2985(96)80024-6
10.1002/eji.200838250
10.1016/j.molimm.2008.06.006
10.4049/jimmunol.161.7.3767
10.1038/ni1496
10.1016/j.immuni.2008.05.008
10.4049/jimmunol.157.12.5721
10.1212/WNL.51.3.758
10.1212/WNL.57.2.342
10.1002/eji.200838879
10.1016/j.molimm.2007.03.002
10.1007/0-387-24361-5_2
10.4049/jimmunol.161.12.6480
10.1093/intimm/dxh379
10.1073/pnas.96.12.6873
10.1146/annurev.immunol.23.021704.115707
10.1038/nrrheum.2009.237
10.1016/j.jneuroim.2008.04.036
10.1002/eji.200939568
10.1586/14737175.5.2.153
10.4049/jimmunol.146.9.2983
10.4049/jimmunol.175.10.6327
10.1038/nature04753
10.4049/jimmunol.173.8.5209
10.4049/jimmunol.170.9.4776
10.1038/ni1430
10.1084/jem.20060285
10.4049/jimmunol.0901906
10.1038/nm.2110
10.1016/S0165-5728(98)00162-3
10.1016/j.jneuroim.2003.10.035
10.4049/jimmunol.164.4.2193
10.1212/WNL.57.8.1371
10.1016/S0165-5728(99)00198-8
10.1189/jlb.0307157
10.1016/S0165-5728(02)00056-5
10.1084/jem.20070850
10.1016/S0165-5728(00)00384-2
10.1016/0165-5728(93)90244-S
10.1038/nri2394
10.1038/ni.1610
10.1146/annurev.iy.10.040192.001101
10.1182/blood-2004-07-2823
10.1016/j.bbi.2010.01.014
10.1073/pnas.2230460100
10.1016/j.immuni.2008.03.011
10.4049/jimmunol.180.8.5267
10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L
10.4049/jimmunol.171.10.5233
10.4049/jimmunol.138.12.4229
10.1146/annurev.immunol.23.021704.115839
10.1089/jir.1998.18.415
10.1016/S0165-5728(03)00210-8
10.1073/pnas.2533866100
10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D
10.1002/(SICI)1098-1136(20000201)29:3<273::AID-GLIA8>3.0.CO;2-9
ContentType Journal Article
Copyright The Author(s) 2010
Copyright_xml – notice: The Author(s) 2010
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7T5
7TK
H94
DOI 10.1177/1352458510381259
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Immunology Abstracts
Neurosciences Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Neurosciences Abstracts
Immunology Abstracts
DatabaseTitleList MEDLINE

CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1477-0970
EndPage 1473
ExternalDocumentID 10_1177_1352458510381259
20935030
10.1177_1352458510381259
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Canadian Institutes of Health Research
  grantid: MOP 1504
GroupedDBID ---
-MK
-TM
.2E
.2F
.2G
.2J
.2N
01A
0R~
123
18M
1~K
29M
31R
31S
31U
31X
31Y
31Z
36B
39C
3V.
4.4
53G
54M
5VS
7X7
88E
8FI
8FJ
8R4
8R5
AABMB
AABOD
AACKU
AACMV
AACTG
AADTT
AADUE
AAEWN
AAGGD
AAGMC
AAJIQ
AAJOX
AAJPV
AAKGS
AAMGE
AANSI
AAPEO
AAQDB
AAQXH
AARDL
AARIX
AATAA
AATBZ
AAUAS
AAXOT
AAYTG
AAZBJ
ABAFQ
ABAWC
ABAWP
ABCCA
ABDWY
ABEIX
ABFWQ
ABHFT
ABHKI
ABHQH
ABJIS
ABJNI
ABKRH
ABLUO
ABNCE
ABPGX
ABPNF
ABQKF
ABQXT
ABRHV
ABUWG
ABVFX
ABVVC
ABYTW
ACARO
ACDSZ
ACDXX
ACFEJ
ACFMA
ACFYK
ACGBL
ACGFO
ACGFS
ACGZU
ACJTF
ACLFY
ACLHI
ACLZU
ACNXM
ACOFE
ACOXC
ACPRK
ACROE
ACSBE
ACSIQ
ACTQU
ACUAV
ACUIR
ACXKE
ACXMB
ADBBV
ADEIA
ADMPF
ADNBR
ADRRZ
ADTBJ
ADUCT
ADUKL
ADZYD
ADZZY
AECGH
AECVZ
AEDTQ
AEKYL
AENEX
AEPTA
AEQLS
AERKM
AESZF
AEUHG
AEUIJ
AEWDL
AEWHI
AEXFG
AEXNY
AFEET
AFKBI
AFKRA
AFKRG
AFMOU
AFQAA
AFUIA
AGKLV
AGNHF
AGWFA
AHHFK
AHMBA
AIGRN
AIOMO
AJABX
AJEFB
AJMMQ
AJSCY
AJUZI
AJXAJ
ALIPV
ALJHS
ALMA_UNASSIGNED_HOLDINGS
ALTZF
AMCVQ
ANDLU
ARTOV
ASPBG
AUTPY
AVWKF
AYAKG
AZFZN
AZQEC
B3H
B8M
B8O
B8R
B8Z
B93
B94
BBRGL
BDDNI
BENPR
BKIIM
BKNYI
BKSCU
BPACV
BPHCQ
BSEHC
BVXVI
BWJAD
BYIEH
CAG
CBRKF
CCPQU
CDWPY
CFDXU
COF
CORYS
CQQTX
CS3
CUTAK
DB0
DC-
DC0
DD-
DD0
DE-
DF0
DO-
DOPDO
DU5
DV7
DV9
D~Y
EBS
EJD
EMOBN
ESX
F5P
FD6
FEDTE
FHBDP
FYUFA
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
HF~
HMCUK
HVGLF
HZ~
J8X
JCYGO
K.F
K.J
K9-
M0R
M1P
M4V
N9A
O9-
P.B
P2P
PQQKQ
PROAC
PSQYO
Q1R
Q2X
Q7K
Q7L
Q7R
Q7U
Q7X
Q82
Q83
ROL
S01
SCNPE
SDB
SFB
SFC
SFK
SFN
SFT
SGA
SGO
SGP
SGR
SGV
SGX
SGZ
SHG
SNB
SPJ
SPQ
SPV
SQCSI
STM
UKHRP
XJT
ZONMY
ZPPRI
ZRKOI
ZSSAH
ACJER
AFVCE
AGWNL
AJXGE
ALKWR
CGR
CUY
CVF
ECM
EIF
H13
NPM
AAYXX
CITATION
7X8
7T5
7TK
H94
ID FETCH-LOGICAL-c368t-79ab3b5815798a0e53e14764513c22123598eff95b6559f48111466f2dc96de23
ISSN 1352-4585
IngestDate Fri Aug 16 07:27:05 EDT 2024
Tue Aug 27 04:37:44 EDT 2024
Wed Sep 11 14:10:53 EDT 2024
Tue Oct 15 23:39:08 EDT 2024
Tue Jul 16 20:53:09 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords experimental autoimmune encephalomyelitis (EAE)
interferon-β
autoimmune disease
Th17
multiple sclerosis
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c368t-79ab3b5815798a0e53e14764513c22123598eff95b6559f48111466f2dc96de23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 20935030
PQID 815555263
PQPubID 23479
PageCount 16
ParticipantIDs proquest_miscellaneous_874179006
proquest_miscellaneous_815555263
crossref_primary_10_1177_1352458510381259
pubmed_primary_20935030
sage_journals_10_1177_1352458510381259
PublicationCentury 2000
PublicationDate 2010-12-01
PublicationDateYYYYMMDD 2010-12-01
PublicationDate_xml – month: 12
  year: 2010
  text: 2010-12-01
  day: 01
PublicationDecade 2010
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: England
PublicationTitle Multiple sclerosis
PublicationTitleAlternate Mult Scler
PublicationYear 2010
Publisher SAGE Publications
Publisher_xml – name: SAGE Publications
References Abdul-Majid KB, Wefer J., Stadelmann C. 2003; 141
Rottman JB, Slavin AJ, Silva R., Weiner HL, Gerard CG, Hancock WW 2000; 30
Ruuls SR, de Labie MC, Weber KS 1996; 157
Sospedra M., Martin R. 2005; 23
Deonarain R., Verma A., Porter AC, Gewert DR, Platanias LC, Fish EN 2003; 100
Watts TH 2005; 23
Sutton C., Brereton C., Keogh B., Mills KH, Lavelle EC 2006; 203
McManus CM, Liu JS, Hahn MT 2000; 29
Toft-Hansen H., Nuttall RK, Edwards DR, Owens T. 2004; 173
Kober J., Leitner J., Klauser C. 2008; 38
Jager A., Dardalhon V., Sobel RA, Bettelli E., Kuchroo VK 2009; 183
Noronha A., Toscas A., Jensen MA 1993; 46
Martin-Saavedra FM, Gonzalez-Garcia C., Bravo B., Ballester S. 2008; 45
Hall JC, Rosen A. 2010; 6
Zhou Q., Rammohan K., Lin S. 2003; 100
Robertson SJ, Messer RJ, Carmody AB, Mittler RS, Burlak C., Hasenkrug KJ 2008; 180
Bettelli E., Carrier Y., Gao W. 2006; 441
Sorensen TL, Sellebjerg F. 2001; 57
Bullard DC, Hu X., Schoeb TR, Axtell RC, Raman C., Barnum SR 2005; 175
Nagai T., Devergne O., Mueller TF, Perkins DL, van Seventer JM, van Seventer GA 2003; 171
Murooka TT, Ward SE, Fish EN 2005; 126
Murphy AC, Lalor SJ, Lynch MA, Mills KH 2010; 24
Tran EH, Kuziel WA, Owens T. 2000; 30
Prinz M., Schmidt H., Mildner A. 2008; 28
Pirhonen J., Siren J., Julkunen I., Matikainen S. 2007; 82
Demeure CE, Tanaka H., Mateo V., Rubio M., Delespesse G., Sarfati M. 2000; 164
Chen M., Chen G., Nie H. 2009; 39
Burks J. 2005; 5
Hilpert J., Beekman JM, Schwenke S. 2008; 199
Fish EN 2008; 8
Okuda Y., Sakoda S., Bernard CC, Yanagihara T. 1998; 18
Piccio L., Vermi W., Boles KS 2005; 105
Mannie MD, Dinarello CA, Paterson PY 1987; 138
Matsuki T., Nakae S., Sudo K., Horai R., Iwakura Y. 2006; 18
Molnarfi N., Gruaz L., Dayer JM, Burger D. 2004; 146
Bruck W., Sommermeier N., Bergmann M. 1996; 195
Jander S., Stoll G. 1998; 91
Teuscher C., Bunn JY, Fillmore PD, Butterfield RJ, Zachary JF, Blankenhorn EP 2004; 165
de Jong BA, Huizinga TW, Bollen EL 2002; 126
Martin-Saavedra FM, Flores N., Dorado B. 2007; 44
Luca ME, Visser L., Lucas CJ, Nagelkerken L. 1999; 100
Teige I., Treschow A., Teige A. 2003; 170
Smith-Bouvier DL, Divekar AA, Sasidhar M. 2008; 205
Tran EH, Hoekstra K., van Rooijen N., Dijkstra CD, Owens T. 1998; 161
Balashov KE, Rottman JB, Weiner HL, Hancock WW 1999; 96
Axtell RC, de Jong BA, Boniface K. 2010; 16
Nicoletti F., Di Marco R., Mangano K. 2001; 57
Tuohy VK, Yu M., Yin L., Mathisen PM, Johnson JM, Kawczak JA 2000; 111
Jacobs CA, Baker PE, Roux ER 1991; 146
Bailey SL, Schreiner B., McMahon EJ, Miller SD 2007; 8
Martin R., McFarland HF, McFarlin DE 1992; 10
Manel N., Unutmaz D., Littman DR 2008; 9
Krishnamoorthy G., Wekerle H. 2009; 39
Acosta-Rodriguez EV, Napolitani G., Lanzavecchia A., Sallusto F. 2007; 8
Silver NC, Lai M., Symms MR, Barker GJ, McDonald WI, Miller DH 1998; 51
Samoilova EB, Horton JL, Hilliard B., Liu TS, Chen Y. 1998; 161
Haak S., Croxford AL, Kreymborg K. 2009; 119
Shinohara ML, Kim JH, Garcia VA, Cantor H. 2008; 29
atypb9
Samoilova EB (atypb33) 1998; 161
atypb8
Jacobs CA (atypb47) 1991; 146
atypb49
atypb44
atypb45
atypb46
atypb40
atypb41
Haak S. (atypb34) 2009; 119
atypb42
atypb43
Ruuls SR (atypb17) 1996; 157
atypb15
atypb16
atypb18
atypb11
atypb55
atypb12
atypb56
atypb13
atypb57
atypb14
atypb58
atypb1
atypb51
atypb52
atypb3
atypb53
atypb2
atypb10
atypb54
atypb4
atypb7
atypb6
atypb50
atypb19
atypb26
atypb27
atypb28
atypb29
atypb22
atypb23
atypb24
atypb25
Tran EH (atypb5) 1998; 161
atypb20
atypb21
Mannie MD (atypb48) 1987; 138
atypb37
atypb38
atypb39
atypb35
atypb36
atypb30
atypb31
atypb32
References_xml – volume: 57
  start-page: 1371
  year: 2001
  end-page: 1376
  article-title: Distinct chemokine receptor and cytokine expression profile in secondary progressive MS
  publication-title: Neurology
  contributor:
    fullname: Sellebjerg F.
– volume: 18
  start-page: 415
  year: 1998
  end-page: 421
  article-title: The development of autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein is associated with an upregulation of both proinflammatory and immunoregulatory cytokines in the central nervous system
  publication-title: J Interferon Cytokine Res
  contributor:
    fullname: Yanagihara T.
– volume: 23
  start-page: 683
  year: 2005
  end-page: 747
  article-title: Immunology of multiple sclerosis
  publication-title: Annu Rev Immunol
  contributor:
    fullname: Martin R.
– volume: 126
  start-page: 15
  year: 2005
  end-page: 44
  article-title: Chemokines and cancer
  publication-title: Cancer Treat Res
  contributor:
    fullname: Fish EN
– volume: 10
  start-page: 153
  year: 1992
  end-page: 187
  article-title: Immunological aspects of demyelinating diseases
  publication-title: Annu Rev Immunol
  contributor:
    fullname: McFarlin DE
– volume: 100
  start-page: 190
  year: 1999
  end-page: 196
  article-title: IFN-beta modulates specific T cell responses in vitro but does not affect Experimental Autoimmune Encephalomyelitis in the SJL mouse
  publication-title: J Neuroimmunol
  contributor:
    fullname: Nagelkerken L.
– volume: 57
  start-page: 342
  year: 2001
  end-page: 344
  article-title: Increased serum levels of interleukin-18 in patients with multiple sclerosis
  publication-title: Neurology
  contributor:
    fullname: Mangano K.
– volume: 8
  start-page: 942
  year: 2007
  end-page: 949
  article-title: Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells
  publication-title: Nat Immunol
  contributor:
    fullname: Sallusto F.
– volume: 175
  start-page: 6327
  year: 2005
  end-page: 6333
  article-title: Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis
  publication-title: J Immunol
  contributor:
    fullname: Barnum SR
– volume: 9
  start-page: 641
  year: 2008
  end-page: 649
  article-title: The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat
  publication-title: Nat Immunol
  contributor:
    fullname: Littman DR
– volume: 170
  start-page: 4776
  year: 2003
  end-page: 4784
  article-title: IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis
  publication-title: J Immunol
  contributor:
    fullname: Teige A.
– volume: 28
  start-page: 675
  year: 2008
  end-page: 686
  article-title: Distinct and non-redundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system
  publication-title: Immunity
  contributor:
    fullname: Mildner A.
– volume: 161
  start-page: 6480
  year: 1998
  end-page: 6486
  article-title: IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells
  publication-title: J Immunol
  contributor:
    fullname: Chen Y.
– volume: 29
  start-page: 68
  year: 2008
  end-page: 78
  article-title: Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin
  publication-title: Immunity
  contributor:
    fullname: Cantor H.
– volume: 146
  start-page: 76
  year: 2004
  end-page: 83
  article-title: Opposite effects of IFN-beta on cytokine homeostasis in LPSand T cell contact-activated human monocytes
  publication-title: J Neuroimmunol
  contributor:
    fullname: Burger D.
– volume: 146
  start-page: 2983
  year: 1991
  end-page: 2989
  article-title: Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor
  publication-title: J Immunol
  contributor:
    fullname: Roux ER
– volume: 180
  start-page: 5267
  year: 2008
  end-page: 5274
  article-title: CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells
  publication-title: J Immunol
  contributor:
    fullname: Hasenkrug KJ
– volume: 5
  start-page: 153
  year: 2005
  end-page: 164
  article-title: Interferon-beta1b for multiple sclerosis
  publication-title: Expert Rev Neurother
  contributor:
    fullname: Burks J.
– volume: 96
  start-page: 6873
  year: 1999
  end-page: 6878
  article-title: CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions
  publication-title: Proc Natl Acad Sci U S A
  contributor:
    fullname: Hancock WW
– volume: 126
  start-page: 172
  year: 2002
  end-page: 179
  article-title: Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis
  publication-title: J Neuroimmunol
  contributor:
    fullname: Bollen EL
– volume: 51
  start-page: 758
  year: 1998
  end-page: 764
  article-title: Serial magnetization transfer imaging to characterize the early evolution of new MS lesions
  publication-title: Neurology
  contributor:
    fullname: Miller DH
– volume: 203
  start-page: 1685
  year: 2006
  end-page: 1691
  article-title: A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis
  publication-title: J Exp Med
  contributor:
    fullname: Lavelle EC
– volume: 8
  start-page: 737
  year: 2008
  end-page: 744
  article-title: The X-files in immunity: sex-based differences predispose immune responses
  publication-title: Nat Rev Immunol
  contributor:
    fullname: Fish EN
– volume: 44
  start-page: 3597
  year: 2007
  end-page: 3607
  article-title: Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis
  publication-title: Mol Immunol
  contributor:
    fullname: Dorado B.
– volume: 38
  start-page: 2678
  year: 2008
  end-page: 2688
  article-title: The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells
  publication-title: Eur J Immunol
  contributor:
    fullname: Klauser C.
– volume: 164
  start-page: 2193
  year: 2000
  end-page: 2199
  article-title: CD47 engagement inhibits cytokine production and maturation of human dendritic cells
  publication-title: J Immunol
  contributor:
    fullname: Sarfati M.
– volume: 195
  start-page: 588
  year: 1996
  end-page: 600
  article-title: Macrophages in multiple sclerosis
  publication-title: Immunobiology
  contributor:
    fullname: Bergmann M.
– volume: 46
  start-page: 145
  year: 1993
  end-page: 153
  article-title: Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis
  publication-title: J Neuroimmunol
  contributor:
    fullname: Jensen MA
– volume: 18
  start-page: 399
  year: 2006
  end-page: 407
  article-title: Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis
  publication-title: Int Immunol
  contributor:
    fullname: Iwakura Y.
– volume: 39
  start-page: 2525
  year: 2009
  end-page: 2536
  article-title: Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS
  publication-title: Eur J Immunol
  contributor:
    fullname: Nie H.
– volume: 119
  start-page: 61
  year: 2009
  end-page: 69
  article-title: IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice
  publication-title: J Clin Invest
  contributor:
    fullname: Kreymborg K.
– volume: 111
  start-page: 55
  year: 2000
  end-page: 63
  article-title: Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis
  publication-title: J Neuroimmunol
  contributor:
    fullname: Kawczak JA
– volume: 39
  start-page: 2031
  year: 2009
  end-page: 2035
  article-title: EAE: an immunologist’s magic eye
  publication-title: Eur J Immunol
  contributor:
    fullname: Wekerle H.
– volume: 173
  start-page: 5209
  year: 2004
  end-page: 5218
  article-title: Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis
  publication-title: J Immunol
  contributor:
    fullname: Owens T.
– volume: 8
  start-page: 172
  year: 2007
  end-page: 180
  article-title: CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in relapsing EAE
  publication-title: Nat Immunol
  contributor:
    fullname: Miller SD
– volume: 205
  start-page: 1099
  year: 2008
  end-page: 1108
  article-title: A role for sex chromosome complement in the female bias in autoimmune disease
  publication-title: J Exp Med
  contributor:
    fullname: Sasidhar M.
– volume: 16
  start-page: 406
  year: 2010
  end-page: 412
  article-title: T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis
  publication-title: Nat Med
  contributor:
    fullname: Boniface K.
– volume: 23
  start-page: 23
  year: 2005
  end-page: 68
  article-title: TNF/TNFR family members in costimulation of T cell responses
  publication-title: Annu Rev Immunol
  contributor:
    fullname: Watts TH
– volume: 157
  start-page: 5721
  year: 1996
  end-page: 5731
  article-title: The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats
  publication-title: J Immunol
  contributor:
    fullname: Weber KS
– volume: 100
  start-page: 13453
  year: 2003
  end-page: 13458
  article-title: Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha
  publication-title: Proc Natl Acad Sci U S A
  contributor:
    fullname: Fish EN
– volume: 165
  start-page: 1593
  year: 2004
  end-page: 1602
  article-title: Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis
  publication-title: Am J Pathol
  contributor:
    fullname: Blankenhorn EP
– volume: 138
  start-page: 4229
  year: 1987
  end-page: 4235
  article-title: Interleukin 1 and myelin basic protein synergistically augment adoptive transfer activity of lymphocytes mediating experimental autoimmune encephalomyelitis in Lewis rats
  publication-title: J Immunol
  contributor:
    fullname: Paterson PY
– volume: 30
  start-page: 2372
  year: 2000
  end-page: 2377
  article-title: Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent
  publication-title: Eur J Immunol
  contributor:
    fullname: Hancock WW
– volume: 29
  start-page: 273
  year: 2000
  end-page: 280
  article-title: Differential induction of chemokines in human microglia by type I and II interferons
  publication-title: Glia
  contributor:
    fullname: Hahn MT
– volume: 91
  start-page: 93
  year: 1998
  end-page: 99
  article-title: Differential induction of interleukin-12, interleukin-18, and interleukin-1beta converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat
  publication-title: J Neuroimmunol
  contributor:
    fullname: Stoll G.
– volume: 45
  start-page: 4008
  year: 2008
  end-page: 4019
  article-title: Beta interferon restricts the inflammatory potential of CD4(+) cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells
  publication-title: Mol Immunol
  contributor:
    fullname: Ballester S.
– volume: 183
  start-page: 7169
  year: 2009
  end-page: 7177
  article-title: Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes
  publication-title: J Immunol
  contributor:
    fullname: Kuchroo VK
– volume: 100
  start-page: 15041
  year: 2003
  end-page: 15046
  article-title: CD24 is a genetic modifier for risk and progression of multiple sclerosis
  publication-title: Proc Natl Acad Sci U S A
  contributor:
    fullname: Lin S.
– volume: 141
  start-page: 10
  year: 2003
  end-page: 19
  article-title: Comparing the pathogenesis of experimental autoimmune encephalomyelitis in CD4-/- and CD8-/- DBA/1 mice defines qualitative roles of different T cell subsets
  publication-title: J Neuroimmunol
  contributor:
    fullname: Stadelmann C.
– volume: 441
  start-page: 235
  year: 2006
  end-page: 238
  article-title: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
  publication-title: Nature
  contributor:
    fullname: Gao W.
– volume: 82
  start-page: 1185
  year: 2007
  end-page: 1192
  article-title: IFN{alpha} regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages
  publication-title: J Leukoc Biol
  contributor:
    fullname: Matikainen S.
– volume: 171
  start-page: 5233
  year: 2003
  end-page: 5243
  article-title: Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation
  publication-title: J Immunol
  contributor:
    fullname: van Seventer GA
– volume: 105
  start-page: 2421
  year: 2005
  end-page: 2427
  article-title: Adhesion of human T cells to antigen-presenting cells through SIRPbeta2CD47 interaction costimulates T-cell proliferation
  publication-title: Blood
  contributor:
    fullname: Boles KS
– volume: 161
  start-page: 3767
  year: 1998
  end-page: 3775
  article-title: Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice
  publication-title: J Immunol
  contributor:
    fullname: Owens T.
– volume: 199
  start-page: 115
  year: 2008
  end-page: 125
  article-title: Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers
  publication-title: J Neuroimmunol
  contributor:
    fullname: Schwenke S.
– volume: 24
  start-page: 641
  year: 2010
  end-page: 651
  article-title: Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis
  publication-title: Brain Behav Immun
  contributor:
    fullname: Mills KH
– volume: 30
  start-page: 1410
  year: 2000
  end-page: 1415
  article-title: Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor
  publication-title: Eur J Immunol
  contributor:
    fullname: Owens T.
– volume: 6
  start-page: 40
  year: 2010
  end-page: 49
  article-title: Type I interferons: crucial participants in disease amplification in autoimmunity
  publication-title: Nat Rev Rheumatol
  contributor:
    fullname: Rosen A.
– ident: atypb11
  doi: 10.1016/S0002-9440(10)63416-5
– ident: atypb4
  doi: 10.1016/S0171-2985(96)80024-6
– ident: atypb28
  doi: 10.1002/eji.200838250
– ident: atypb37
  doi: 10.1016/j.molimm.2008.06.006
– volume: 161
  start-page: 3767
  year: 1998
  ident: atypb5
  publication-title: J Immunol
  doi: 10.4049/jimmunol.161.7.3767
  contributor:
    fullname: Tran EH
– ident: atypb57
  doi: 10.1038/ni1496
– ident: atypb40
  doi: 10.1016/j.immuni.2008.05.008
– volume: 157
  start-page: 5721
  year: 1996
  ident: atypb17
  publication-title: J Immunol
  doi: 10.4049/jimmunol.157.12.5721
  contributor:
    fullname: Ruuls SR
– ident: atypb3
  doi: 10.1212/WNL.51.3.758
– ident: atypb45
  doi: 10.1212/WNL.57.2.342
– ident: atypb39
  doi: 10.1002/eji.200838879
– ident: atypb38
  doi: 10.1016/j.molimm.2007.03.002
– ident: atypb52
  doi: 10.1007/0-387-24361-5_2
– volume: 161
  start-page: 6480
  year: 1998
  ident: atypb33
  publication-title: J Immunol
  doi: 10.4049/jimmunol.161.12.6480
  contributor:
    fullname: Samoilova EB
– ident: atypb46
  doi: 10.1093/intimm/dxh379
– ident: atypb53
  doi: 10.1073/pnas.96.12.6873
– ident: atypb1
  doi: 10.1146/annurev.immunol.23.021704.115707
– ident: atypb22
  doi: 10.1038/nrrheum.2009.237
– ident: atypb31
  doi: 10.1016/j.jneuroim.2008.04.036
– ident: atypb10
  doi: 10.1002/eji.200939568
– ident: atypb7
  doi: 10.1586/14737175.5.2.153
– volume: 146
  start-page: 2983
  year: 1991
  ident: atypb47
  publication-title: J Immunol
  doi: 10.4049/jimmunol.146.9.2983
  contributor:
    fullname: Jacobs CA
– ident: atypb56
  doi: 10.4049/jimmunol.175.10.6327
– ident: atypb32
  doi: 10.1038/nature04753
– ident: atypb8
  doi: 10.4049/jimmunol.173.8.5209
– ident: atypb14
  doi: 10.4049/jimmunol.170.9.4776
– ident: atypb58
  doi: 10.1038/ni1430
– volume: 119
  start-page: 61
  year: 2009
  ident: atypb34
  publication-title: J Clin Invest
  contributor:
    fullname: Haak S.
– ident: atypb50
  doi: 10.1084/jem.20060285
– ident: atypb6
  doi: 10.4049/jimmunol.0901906
– ident: atypb36
  doi: 10.1038/nm.2110
– ident: atypb44
  doi: 10.1016/S0165-5728(98)00162-3
– ident: atypb23
  doi: 10.1016/j.jneuroim.2003.10.035
– ident: atypb26
  doi: 10.4049/jimmunol.164.4.2193
– ident: atypb54
  doi: 10.1212/WNL.57.8.1371
– ident: atypb15
  doi: 10.1016/S0165-5728(99)00198-8
– ident: atypb43
  doi: 10.1189/jlb.0307157
– ident: atypb51
  doi: 10.1016/S0165-5728(02)00056-5
– ident: atypb19
  doi: 10.1084/jem.20070850
– ident: atypb16
  doi: 10.1016/S0165-5728(00)00384-2
– ident: atypb21
  doi: 10.1016/0165-5728(93)90244-S
– ident: atypb18
  doi: 10.1038/nri2394
– ident: atypb42
  doi: 10.1038/ni.1610
– ident: atypb20
  doi: 10.1146/annurev.iy.10.040192.001101
– ident: atypb27
  doi: 10.1182/blood-2004-07-2823
– ident: atypb35
  doi: 10.1016/j.bbi.2010.01.014
– ident: atypb9
  doi: 10.1073/pnas.2230460100
– ident: atypb41
  doi: 10.1016/j.immuni.2008.03.011
– ident: atypb30
  doi: 10.4049/jimmunol.180.8.5267
– ident: atypb13
  doi: 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L
– ident: atypb24
  doi: 10.4049/jimmunol.171.10.5233
– volume: 138
  start-page: 4229
  year: 1987
  ident: atypb48
  publication-title: J Immunol
  doi: 10.4049/jimmunol.138.12.4229
  contributor:
    fullname: Mannie MD
– ident: atypb29
  doi: 10.1146/annurev.immunol.23.021704.115839
– ident: atypb49
  doi: 10.1089/jir.1998.18.415
– ident: atypb2
  doi: 10.1016/S0165-5728(03)00210-8
– ident: atypb25
  doi: 10.1073/pnas.2533866100
– ident: atypb12
  doi: 10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D
– ident: atypb55
  doi: 10.1002/(SICI)1098-1136(20000201)29:3<273::AID-GLIA8>3.0.CO;2-9
SSID ssj0007735
Score 2.2349143
Snippet Background: Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Objectives:...
Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Our objective was to...
Background: Interferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined. Objectives:...
BACKGROUNDInterferon (IFN)-β is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined.OBJECTIVESOur...
Background: Interferon (IFN)- beta is an effective therapy for relapsing-remitting multiple sclerosis, yet its mechanism of action remains ill-defined....
SourceID proquest
crossref
pubmed
sage
SourceType Aggregation Database
Index Database
Publisher
StartPage 1458
SubjectTerms Animals
Autoimmunity - immunology
Cell Separation
Cytokines - biosynthesis
Cytokines - immunology
Encephalomyelitis, Autoimmune, Experimental - immunology
Encephalomyelitis, Autoimmune, Experimental - metabolism
Encephalomyelitis, Autoimmune, Experimental - pathology
Female
Flow Cytometry
Gene Expression Profiling
Immunohistochemistry
Inflammation - immunology
Inflammation - metabolism
Inflammation - pathology
Interferon-beta - immunology
Interferon-beta - metabolism
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Th17 Cells - immunology
Th17 Cells - metabolism
Title Interferon-β is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis
URI https://journals.sagepub.com/doi/full/10.1177/1352458510381259
https://www.ncbi.nlm.nih.gov/pubmed/20935030
https://search.proquest.com/docview/815555263
https://search.proquest.com/docview/874179006
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJiFeEHfKZfIDQ0JVRuLEt0daFSbEJoQ6qW-RmzpbJJZMTfqw_Qf-DD-E38RxnDrpBTToQ1RZbuz6HPt89vl8DkJvBGMc5ljghWAPvIjowJNKK08lgshEqMif1yzfU3Z8Fn2e0mmv96PDWlpWs6PkZue9kv-RKpSBXM0t2X-QrHspFMB3kC88QcLwvJWM6-O8VC-K3DscjQ-HxKQnVwOYl4OFzTFf1E4AWCWhOZD9pfWp11GbaiLsWoB_tayKzNwX0QMz368u1Pfi8lobglzZBbEnKxJiCf0BK5s5XP5JmfCe9kx19KVddh2Zpj0aBwkDvq-h68QRtYcqO2-vRzSHEVvEDusF23neGADS8yJq8_McaVsWce750mYOccsx66od6SyuQWSjvDeGGn4d7jYCtRvaNGjaMxHgAcXJ1uA5GmJTOd6segftEy6pYYjyqdu_-5zX-VrdP2m93u8337COcra2Lmu0wRrJTB6g-80WBH-w-vQQ9XT-CN09aUgWj9F5R61-_cRZiRUGlcJOpXCR4g2VwlalcJbjrkrhVqXwlko9QWcfx5PRsdfk4_CSkInK41LNwhkVAeVSKF_TUIMMWESDMCEGAlEpdJpKOmOwT00jEZgr7ywl80SyuSbhU7SXF7l-jnDkh4CcSMoAMkYpDRRRjNG5EEIy2MLzPnq3Gr_4yoZdiYMmMv3mWPcRXg1wDGujcXipXBfLMoaewoew8C9VuEnBB6anj55Z2bj2iOEIgA3so7dGWHEz8cs_duTFbSu-RPfayfMK7VWLpX4N2LaaHdQad4D2h-PTr99-A8DvnKM
link.rule.ids 315,786,790,27955,27956,31753,33778
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interferon-%CE%B2+is+a+key+regulator+of+proinflammatory+events+in+experimental+autoimmune+encephalomyelitis&rft.jtitle=Multiple+sclerosis&rft.au=Galligan%2C+CL&rft.au=Pennell%2C+LM&rft.au=Murooka%2C+TT&rft.au=Baig%2C+E&rft.date=2010-12-01&rft.pub=SAGE+Publications&rft.issn=1352-4585&rft.eissn=1477-0970&rft.volume=16&rft.issue=12&rft.spage=1458&rft.epage=1473&rft_id=info:doi/10.1177%2F1352458510381259&rft.externalDocID=10.1177_1352458510381259
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1352-4585&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1352-4585&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1352-4585&client=summon